{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:05:01Z","timestamp":1780592701415,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":23,"publisher":"Springer US","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/7651_2026_711","type":"book-chapter","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:30:12Z","timestamp":1780590612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modeling Melanoma Immune Surveillance by CAR-T Cells in Human Skin Organoids"],"prefix":"10.1007","author":[{"given":"Korvell","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Shivde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanin","family":"Abuzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cormac","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalyne","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Caroline","family":"LePoole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany E.","family":"Perez White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"1","key":"711_CR1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41467-024-45221-2","volume":"15","author":"S Jilani","year":"2024","unstructured":"Jilani S et al (2024) CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. Nat Commun 15(1):1244","journal-title":"Nat Commun"},{"issue":"1","key":"711_CR2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","volume":"14","author":"J Edeline","year":"2021","unstructured":"Edeline J et al (2021) CAR-T cells and BiTEs in solid tumors: challenges and perspectives. J Hematol Oncol 14(1):65","journal-title":"J Hematol Oncol"},{"issue":"12","key":"711_CR3","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/exd.13792","volume":"27","author":"B Simon","year":"2018","unstructured":"Simon B, Uslu U (2018) CAR-T cell therapy in melanoma: a future success story? Exp Dermatol 27(12):1315\u20131321","journal-title":"Exp Dermatol"},{"issue":"11","key":"711_CR4","volume":"6","author":"G Escobar","year":"2025","unstructured":"Escobar G, Berger TR, Maus MV (2025) CAR-T cells in solid tumors: challenges and breakthroughs. Cell Rep Med 6(11):102353","journal-title":"Cell Rep Med"},{"issue":"6","key":"711_CR5","doi-asserted-by":"crossref","first-page":"e011698","DOI":"10.1136\/jitc-2025-011698","volume":"13","author":"D Andreu-Sanz","year":"2025","unstructured":"Andreu-Sanz D et al (2025) Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis. J Immunother Cancer 13(6):e011698","journal-title":"J Immunother Cancer"},{"key":"711_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ebiom.2019.01.029","volume":"40","author":"Y Wu","year":"2019","unstructured":"Wu Y, Yu XZ (2019) Modelling CAR-T therapy in humanized mice. EBioMedicine 40:25\u201326","journal-title":"EBioMedicine"},{"issue":"1","key":"711_CR7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day CP, Merlino G, Van Dyke T (2015) Preclinical mouse cancer models: a maze of opportunities and challenges. Cell 163(1):39\u201353","journal-title":"Cell"},{"issue":"8","key":"711_CR8","doi-asserted-by":"crossref","first-page":"41221","DOI":"10.31083\/FBL41221","volume":"30","author":"J Philippova","year":"2025","unstructured":"Philippova J et al (2025) GD2-specific CAR T cells demonstrate potent and targeted anti-tumor efficacy against melanoma in vitro and in vivo. Front Biosci (Landmark Ed) 30(8):41221","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"3","key":"711_CR9","volume":"32","author":"CS Hackett","year":"2024","unstructured":"Hackett CS et al (2024) TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models. Mol Ther Oncol 32(3):200862","journal-title":"Mol Ther Oncol"},{"issue":"6","key":"711_CR10","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00262-020-02780-9","volume":"70","author":"G de Jong","year":"2021","unstructured":"de Jong G et al (2021) Melanoma cells can be eliminated by sialylated CD43 \u00d7 CD3 bispecific T cell engager formats in vitro and in vivo. Cancer Immunol Immunother 70(6):1569\u20131581","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"711_CR11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/exd.13678","volume":"27","author":"B Simon","year":"2018","unstructured":"Simon B et al (2018) The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma. Exp Dermatol 27(7):769\u2013778","journal-title":"Exp Dermatol"},{"issue":"1","key":"711_CR12","doi-asserted-by":"crossref","first-page":"104286","DOI":"10.1016\/j.xpro.2025.104286","volume":"7","author":"CA Palin","year":"2026","unstructured":"Palin CA, Jenkins RW, Revach O-Y (2026) Protocol for the preparation and analysis of patient-derived organotypic tumor spheroids. STAR Protocols 7(1):104286","journal-title":"STAR Protocols"},{"issue":"7","key":"711_CR13","volume":"6","author":"OY Revach","year":"2025","unstructured":"Revach OY et al (2025) Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants. Cell Rep Med 6(7):102210","journal-title":"Cell Rep Med"},{"key":"711_CR14","doi-asserted-by":"crossref","first-page":"1626369","DOI":"10.3389\/fimmu.2025.1626369","volume":"16","author":"M Jassin","year":"2025","unstructured":"Jassin M et al (2025) From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors. Front Immunol 16:1626369","journal-title":"Front Immunol"},{"issue":"1","key":"711_CR15","volume":"33","author":"ACM Domingues","year":"2025","unstructured":"Domingues ACM et al (2025) Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade. Mol Ther Oncol 33(1):200942","journal-title":"Mol Ther Oncol"},{"key":"711_CR16","volume":"92","author":"L Ou","year":"2023","unstructured":"Ou L et al (2023) Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. EBioMedicine 92:104614","journal-title":"EBioMedicine"},{"issue":"8","key":"711_CR17","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jid.2024.01.014","volume":"144","author":"BE Perez White","year":"2024","unstructured":"Perez White BE et al (2024) Receptor tyrosine kinase EPHA2 drives epidermal differentiation through regulation of EGFR signaling. J Invest Dermatol 144(8):1798\u20131807.e1","journal-title":"J Invest Dermatol"},{"issue":"1","key":"711_CR18","first-page":"111","volume":"130","author":"BE Perez White","year":"2017","unstructured":"Perez White BE et al (2017) EphA2 proteomics in human keratinocytes reveals a novel association with afadin and epidermal tight junctions. J Cell Sci 130(1):111\u2013118","journal-title":"J Cell Sci"},{"key":"711_CR19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/bs.mie.2015.07.015","volume":"569","author":"C Arnette","year":"2016","unstructured":"Arnette C et al (2016) In vitro model of the epidermis: connecting protein function to 3D structure. Methods Enzymol 569:287\u2013308","journal-title":"Methods Enzymol"},{"key":"711_CR20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-60761-380-0_10","volume":"585","author":"CL Simpson","year":"2010","unstructured":"Simpson CL, Kojima S, Getsios S (2010) RNA interference in keratinocytes and an organotypic model of human epidermis. Methods Mol Biol 585:127\u2013146","journal-title":"Methods Mol Biol"},{"issue":"1","key":"711_CR21","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41467-020-16583-0","volume":"11","author":"S Di Blasio","year":"2020","unstructured":"Di Blasio S et al (2020) The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. Nat Commun 11(1):2749","journal-title":"Nat Commun"},{"issue":"1","key":"711_CR22","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41598-017-00670-2","volume":"7","author":"L Wallmeyer","year":"2017","unstructured":"Wallmeyer L et al (2017) TSLP is a direct trigger for T cell migration in filaggrin-deficient skin equivalents. Sci Rep 7(1):774","journal-title":"Sci Rep"},{"issue":"3","key":"711_CR23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/jid.2013.417","volume":"134","author":"EH van den Bogaard","year":"2014","unstructured":"van den Bogaard EH et al (2014) Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases. J Invest Dermatol 134(3):719\u2013727","journal-title":"J Invest Dermatol"}],"container-title":["Methods in Molecular Biology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7651_2026_711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:30:14Z","timestamp":1780590614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7651_2026_711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1007\/7651_2026_711","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"5 June 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}